Committee on Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, California 92037.
J Neurosci. 2013 Dec 4;33(49):19384-92. doi: 10.1523/JNEUROSCI.1979-13.2013.
The abuse of opioid drugs, both illicit and prescription, is a persistent problem in the United States, accounting for >1.2 million users who require treatment each year. Current treatments rely on suppressing immediate withdrawal symptoms and replacing illicit drug use with long-acting opiate drugs. However, the mechanisms that lead to preventing opiate dependence are still poorly understood. We hypothesized that κ opioid receptor (KOR) activation during chronic opioid intake contributes to negative affective states associated with withdrawal and the motivation to take increasing amounts of heroin. Using a 12 h long-access model of heroin self-administration, rats showed escalation of heroin intake over several weeks. This was prevented by a single high dose (30 mg/kg) of the long-acting KOR antagonist norbinaltorphimine (nor-BNI), paralleled by reduced motivation to respond for heroin on a progressive-ratio schedule of reinforcement, a measure of compulsive-like responding. Systemic nor-BNI also significantly decreased heroin withdrawal-associated anxiety-like behavior. Immunohistochemical analysis showed prodynorphin content increased in the nucleus accumbens core in all heroin-exposed rats, but selectively increased in the nucleus accumbens shell in long-access rats. Local infusion of nor-BNI (4 μg/side) into accumbens core altered the initial intake of heroin but not the rate of escalation, while local injection into accumbens shell selectively suppressed increases in heroin intake over time without altering initial intake. These data suggest that dynorphin activity in the nucleus accumbens mediates the increasing motivation for heroin taking and compulsive-like responding for heroin, suggesting that KOR antagonists may be promising targets for the treatment of opioid addiction.
阿片类药物的滥用,包括非法和处方药物,是美国长期存在的问题,每年有超过 120 万名患者需要接受治疗。目前的治疗方法依赖于抑制即刻戒断症状,并以长效阿片类药物替代非法药物。然而,导致预防阿片类药物依赖的机制仍知之甚少。我们假设在慢性阿片类药物摄入期间,κ 阿片受体(KOR)的激活有助于与戒断相关的负性情绪状态,并导致对海洛因的摄取量增加。使用海洛因自我给药的 12 小时长时程模型,大鼠在数周内表现出海洛因摄入量的增加。单次高剂量(30mg/kg)长效 KOR 拮抗剂诺比那肽(nor-BNI)可预防这种增加,同时在递增比率强化方案(一种强迫性反应的测量)中对海洛因的反应动机降低,这表明存在强迫性反应。全身 nor-BNI 也显著降低了海洛因戒断相关的焦虑样行为。免疫组织化学分析显示,所有海洛因暴露的大鼠伏核核心中的前强啡肽原含量增加,但在长时间接触的大鼠中,仅在伏核壳中增加。在伏核核心中局部输注 nor-BNI(4μg/侧)改变了海洛因的初始摄入量,但不改变递增率,而在伏核壳中局部注射选择性地抑制了海洛因摄入的增加,而不改变初始摄入。这些数据表明,伏核中强啡肽的活性介导了海洛因摄取动机的增加和对海洛因的强迫性反应,这表明 KOR 拮抗剂可能是治疗阿片类药物成瘾的有希望的靶点。